Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)

This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Impairment Alzheimer Disease Brain Diseases Central Nervous System Diseases Cognition Disorders Cognition Disorders in Old Age Cognitive Abnormality Cognitive Change Cognitive Decline Cognitive Deterioration Cognitive Dysfunction Cognitive Impairment, Mild Cognitive Symptom Dementia Dementia Alzheimers Dementia of Alzheimer Type Dementia, Alzheimer Type Dementia, Mild Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Mental Disorders Neoplasms Neoplasms by Histologic Type Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Tauopathies

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The Montreal Cognitive Assessment (MoCA) is a short tool to evaluate a multitude of cognitive domains (visuospatial / executive functioning, object naming, memory, attention, language, abstraction, orientation). The original English MoCA consistently showed very high sensitivity and specificity in distinguishing patients with mild cognitive impairment from healthy controls. Therefore it is an excellent tool for early recognition of cognitive disorders. Based on a Canadian sample, the MoCA proposes a cut-off-value of 26/30 points. However, there is increasing evidence of intercultural differences in terms of the best cut-off-score. In addition the original version only slightly corrects for possible influences of education - an adjustment for age- or gender-related effects is missing. Therefore, the aim of our study was to investigate the possible impacts of demographics on the MoCA total score and to provide normative values for a German-speaking population.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥65 years
Education ≥7 years
Fluency in the German language
Written informed consent

Exclusion criteria

History of cognitive impairment
Depression
Severe sensory or motor impairment interfering with cognitive testing
Serious somatic disease
Disease or event affecting the central nervous system
Cerebrovascular disease
Regular medication with psychoactive drugs except for benzodiazepines
Participation in a cognitive study within the last 3 months

Treatment and study plan

MoCA

Diagnostic Test

Primary outcomes

Montreal Cognitive Assessment (MoCA) - German version

Time frame: Baseline

Total score of the MoCA

Secondary outcomes

Mini-Mental State Examination (MMSE)

Time frame: Baseline

Total score of the MMSE
Geriatric Depression Scale (GDS)

Time frame: Baseline

Total score of the GDS
Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)

Time frame: Baseline

Total score of the CERAD-NAB

Sponsors and collaborators

Lead sponsor

Andreas Monsch

Other

Registry information

Acronym: MoCA-Norm

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Aug 11, 2017
Registry last updated: May 31, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting